TREVISAN, MATTEO
TREVISAN, MATTEO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Impatto della dose iniziale sul trattamento con lenvatinib nel carcinoma tiroideo differenziato avanzato
2025 C. Moneta, M. Trevisan, C. Colombo, M. Succi, M. Lugaresi, D. Ceruti, S. De Leo, L. Fugazzola
Chirurgia robotica nel trattamento del tumore della tiroide
2025 F. Brucchi, D. Barbieri, P. Indelicato, M. Andreani, A.E. Leone, M. Trevisan, M. Raffaelli, G. Materazzi, G. Dionigi
Neuromonitoraggio del ramo esterno del nervo laringeo superiore nella tiroidectomia: una metanalisi
2025 F. Brucchi, D. Barbieri, P. Indelicato, M. Andreani, A.E. Leone, M. Trevisan, M. Raffaelli, G. Materazzi, G. Dionigi
Will the autofluorescence take over inadvertent parathyroidectomy?Results from a multicentre cohort study
2025 D. Barbieri, P. Indelicato, S. DE LEO, C. Moneta, S. Coccia, G. Gazzano, L. Giordano, F. LIRA LUCE, D. Canta, L. Fugazzola, M. Bussi, G. Dionigi, M. Trevisan
Analisi dell’emorragia postoperatoria in oltre 40.000 interventi alla tiroide
2025 F. Brucchi, M. Trevisan, M. Andreani, A.E. Leone, G. Dionigi
Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex
2024 C. Colombo, D. Ceruti, M. Succi, S. De Leo, M. Trevisan, C. Moneta, L. Fugazzola
Management of hypertension during Lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
2023 C. Colombo, D. Ceruti, S. DE LEO, G. Bilo, M. Trevisan, N. Giancola, C. Moneta, G. Parati, L. Persani, L. Fugazzola
Endocrine-related adverse conditions induced by tyrosine kinase inhibitors.
2023 S. De Leo, M. Trevisan, C. Moneta, C. Colombo
Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer
2023 S. De Leo, M. Trevisan, G.V. Re Sartò, C. Moneta, M. Pirovano, C. Colombo, L. Cosmai, L. Fugazzola
Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
2023 S. De Leo, M. Trevisan, C. Colombo, C. Moneta, N. Giancola, L. Fugazzola
Daily Management of Patients on Multikinase Inhibitors' Treatment
2022 C. Colombo, S. De Leo, M. Trevisan, N. Giancola, A. Scaltrito, L. Fugazzola
Persistent Thyroid Carcinoma and Pregnancy: Outcomes in an Italian Series and Review of the Literature
2022 C. Colombo, S. De Leo, N. Giancola, M. Trevisan, D. Ceruti, F. Frattini, L. Persani, L. Fugazzola
SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
2022 M.E. Lunati, V. Cimino, A. Gandolfi, M. Trevisan, L. Montefusco, I. Pastore, C. Pace, N. Betella, G. Favacchio, M. Bulgheroni, L. Bucciarelli, G. Massari, C. Mascardi, A. Girelli, P.S. Morpurgo, F. Folli, L. Luzi, M. Mirani, B. Pintaudi, F. Bertuzzi, C. Berra, P. Fiorina
Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
2022 M. Trevisan, C. Colombo, N. Giancola, C. Moneta, G. Dionigi, L. Fugazzola, S. De Leo
Total Thyroidectomy Versus Lobectomy for Thyroid Cancer: Single-Center Data and Literature Review
2021 C. Colombo, S. De Leo, M. Di Stefano, M. Trevisan, C. Moneta, L. Vicentini, L. Fugazzola
Post-surgical ablative or adjuvant radioiodine therapy has no impact on outcome in 1–4 cm differentiated thyroid cancers without extrathyroidal extension
2021 S. De Leo, M. Trevisan, C. Colombo, G. Gazzano, S. Palazzo, L. Vicentini, L. Persani, L. Fugazzola
The informative experience of endocrine residents with COVID-19
2020 M. Di Stefano, S. Federici, L. Giovanelli, B. Nadiani, F. Nicoli, M. Trevisan